Cream cheese can upgrade just about any bagel to an entirely different level. However, that tasty cream cheese isn't always good for you. These particular cream cheese flavors may actually increase ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...

We’re prostate cancer experts. Here are the benefits of quick and targeted MRI scans - Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prosta ...

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...

In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality ​from dementia is on the rise, a large analysis has found.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...